Zydus gets final USFDA nod to market epilepsy and menopause drugs | Mint
Active Stocks
Mon Feb 26 2024 10:18:11
  1. Tata Steel share price
  2. 144.20 -0.89%
  1. Power Grid Corporation Of India share price
  2. 286.90 1.67%
  1. ITC share price
  2. 411.80 0.05%
  1. State Bank Of India share price
  2. 759.90 0.07%
  1. HDFC Bank share price
  2. 1,422.55 0.12%
Business News/ Companies / News/  Zydus gets final USFDA nod to market epilepsy and menopause drugs
BackBack

Zydus gets final USFDA nod to market epilepsy and menopause drugs

With a market valuation of ₹41,515.55 Cr, Zydus Lifesciences Ltd. is a large cap business that operates in the pharmaceutical industry.

With its headquarters in Ahmedabad, India, Zydus Group is the fourth-ranked pharmaceutical company in the country. (REUTERS)Premium
With its headquarters in Ahmedabad, India, Zydus Group is the fourth-ranked pharmaceutical company in the country. (REUTERS)

With a market valuation of 41,515.55 Cr, Zydus Lifesciences Ltd. is a large-cap business that operates in the pharmaceutical industry. With its headquarters in Ahmedabad, India, Zydus Group is the fourth-ranked pharmaceutical company in the country. Across five Indian states—Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim—as well as in the US and Brazil, the group has production and research facilities.

Today the US Food and Drug Administration (USFDA) has given the firm final approval to market the Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (USRLD: Vivelle-Dot® Transdermal System). The company said while making this announcement that Estradiol Transdermal System is indicated to treat moderate to severe symptoms of menopause which includes feelings of warmth in the face, neck and chest or sudden strong feelings of heat, hot flushes and vaginal dryness in women. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India. The organisation has filed over 431* ANDAs since the filing procedure began in FY 2003–04, and it now has 336 approvals.

The United States Food and Drug Administration (USFDA) granted Zydus Lifesciences Limited final permission yesterday, December 1st, to market Topiramate extended-release capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg (USRLD: Qudexy® XR Extended-Release capsules). According to IQVIA statistics, topiramate Extended-Release capsule had yearly sales of USD 68.8 million in the United States (IQVIA MAT Sep 2022). The organisation has filed over 431* ANDAs since the filing procedure began in FY 2003–04, and it now has 335 approvals. The company said while making this announcement that Topiramate Extended-Release capsule is indicated to prevent and control seizures in people with epilepsy. It may also be used to prevent migraine headaches. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.

On Tuesday, Zydus Lifesciences revealed that it has signed a business transfer agreement to acquire Watson Pharma's active pharmaceutical ingredients (API) business for a one-time payment of 46.77 crore, free of cash and debt. The acquisition is anticipated to be finished by March 31, 2023, and the Business Undertaking of Watson is in the business of producing, manufacturing, marketing, and selling Active Pharmaceutical Ingredients ("APIs").

The shares of Zydus Lifesciences opened today at 410.00 apiece and currently, it is trading at a market price of 411.05 with a downside gap of 0.06%. On a YTD basis, the stock has fallen 13.92% so far in 2022.

 

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

ABOUT THE AUTHOR
Vipul Das
Vipul Das is a Digital Business Content Producer at Livemint. He previously worked for Goodreturns.in (OneIndia News) and has over 5 years of expertise in the finance and business sector. Stocks, mutual funds, personal finance, tax, and banking are among his specialties, and he is a professional in industry research and business reporting. He received his bachelor's degree from Dr. CV Raman University and also have completed Diploma in Journalism and Mass Communication (DJMC).
Catch all the Corporate news and Updates on Live Mint. Check all the latest action on Budget 2024 here. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 02 Dec 2022, 12:28 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App